<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="26139">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02766465</url>
  </required_header>
  <id_info>
    <org_study_id>BMTCTN1503</org_study_id>
    <secondary_id>1U01HL128568-01</secondary_id>
    <nct_id>NCT02766465</nct_id>
  </id_info>
  <brief_title>Bone Marrow Transplantation vs Standard of Care in Patients With Severe Sickle Cell Disease (BMT CTN 1503)</brief_title>
  <acronym>STRIDE2</acronym>
  <official_title>A Study to Compare Bone Marrow Transplantation to Standard Care in Adolescents and Young Adults With Severe Sickle Cell Disease (BMT CTN #1503)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical College of Wisconsin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Blood and Marrow Transplant Clinical Trials Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Marrow Donor Program</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical College of Wisconsin</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a clinical trial that will compare survival and sickle related outcomes in
      adolescents and young adults with severe sickle cell disease after bone marrow
      transplantation and standard of care. The primary outcome is 2-year overall survival.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective phase II multi-center trial of hematopoietic stem cell transplantation
      or standard of care based on availability of HLA-matched related or unrelated donor after
      confirmation of clinical eligibility. In order to minimize bias assignment to either
      treatment arm, clinical eligibility to both treatment arms are similar and donor
      availability is not known at referral. HLA typing and donor search is initiated upon
      confirmation of clinical eligibility for the study. Additionally, all analyses of primary
      and secondary endpoints will follow the Intent-to-Treat principle to address potential bias
      introduced by participants with donors not proceeding to transplantation or those without a
      matched donor receiving transplantation with less well-matched donors.

      The primary outcome is 2-year overall survival. Our hypothesis is that patients who receive
      bone marrow transplantation will experience early deaths but that this will plateau by 2
      years after transplantation. Patients who receive standard of care will not experience early
      death but will succumb to their disease at a rate much higher than the general population.
      Therefore, the goal of the study is to establish that the difference in the proportion of
      patients surviving is not significantly more than 15% lower in the donor arm at 2-years
      after assignment to treatment arm.

      Secondary endpoints will compare changes in sickle cell disease related events (pulmonary
      hypertension, cerebrovascular events, renal function, avascular necrosis, leg ulcer) and
      functional outcomes [6-minute walk distance (6MWD), health-related quality of life, cardiac
      function, pulmonary function, and mean pain intensity as assessed by a multidimensional
      electronic pain diary] from baseline to 2-years after assignment to treatment arms.

      Additionally for patients assigned to the donor arm and expected to undergo transplantation,
      hematopoietic recovery, graft rejection, acute and chronic graft-versus-host disease, other
      significant transplant-related complications and disease-free survival will be reported.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 2016</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>2 Years</time_frame>
    <description>OS will be compared between treatment arms using a point-wise comparison at 2-years, and the survival curves will be estimated using the Kaplan Meier product limit estimator.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurrence of Sickle Cell Disease (SCD) related events</measure>
    <time_frame>2 Years</time_frame>
    <description>Examination of the occurrence of the SCD-related events will be performed. Exact logistic regression will be used to estimate an odds ratio of each of these events between treatment groups, assuming that at least one event occurs on study in each of the treatment groups, controlling for other patient related characteristics and individual history of the event of interest.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Pain Intensity</measure>
    <time_frame>Day 28, 1 year, and 2 years</time_frame>
    <description>Mean pain intensity assessed by an electronic pain diary.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exercise Capacity</measure>
    <time_frame>Day 28, 1 year, and 2 years</time_frame>
    <description>The 6-minute walk distance (6MWD) test will be used to assess exercise capacity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac Function</measure>
    <time_frame>Day 28, 1 year, and 2 years</time_frame>
    <description>Cardiac function will be assessed by the change from baseline in Tricuspid regurgitant jet velocity (TRJV).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary Function</measure>
    <time_frame>Day 28, 1 year, and 2 years</time_frame>
    <description>Pulmonary function will be assessed by the change from baseline in Forced Expiratory Volume 1 second (FEV1).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal Function</measure>
    <time_frame>Day 28, 1 year, and 2 years</time_frame>
    <description>Renal function will be assessed through measurements of albuminuria (urine-albumin creatinine ratio) and serum creatinine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-Related Quality of Life (HRQoL)</measure>
    <time_frame>Day 28, 1 year, and 2 years</time_frame>
    <description>HRQoL assessed using the NIH's PROMIS 57 instrument.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Sickle Cell Disease</condition>
  <arm_group>
    <arm_group_label>Donor Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The donor arm will be treated with a preparative regimen of busulfan, fludarabine, and r-ATG before undergoing the bone marrow transplant. Graft-vs-Host-Disease (GVHD) prophylaxis will be tacrolimus combined with methotrexate.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No-Donor Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>No-donor arm will continue with standard of care per their SCD physician.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Busulfan</intervention_name>
    <description>Busulfan dose will be 3.2 mg/kg administered as a single daily dose IV on days -8 through -5 with dosing adjusted using targeted pharmacokinetics.</description>
    <arm_group_label>Donor Arm</arm_group_label>
    <other_name>Busulfex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Fludarabine dose will be 35 mg/m^2/day administered IV on days -7 through -3 (total fludarabine dose is 175 mg/m^2).</description>
    <arm_group_label>Donor Arm</arm_group_label>
    <other_name>Fludara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>r-ATG</intervention_name>
    <description>r-ATG will be administered IV on day -6 at 0.5mg/kg, on day -5 at 1 mg/kg and on days -4, -3 and -2 at 1.5mg/kg (total r-ATG dose is 6 mg/kg).</description>
    <arm_group_label>Donor Arm</arm_group_label>
    <other_name>Rabbit antithymocyte globulin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Bone Marrow Transplant</intervention_name>
    <description>Day 0 is the day of bone marrow transplantation.</description>
    <arm_group_label>Donor Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>Tacrolimus commences on day -3 and extends through day +180 after transplantation with doses adjusted to maintain appropriate levels according to institutional guidelines.</description>
    <arm_group_label>Donor Arm</arm_group_label>
    <other_name>Prograf®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>Methotrexate will be administered intravenously on day+1 at 15mg/m^2, day+3 at 10mg/m^2, day+6 at 10mg/m^2, and day+11 at 10mg/m^2.</description>
    <arm_group_label>Donor Arm</arm_group_label>
    <other_name>MTX</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Standard of Care</intervention_name>
    <description>Continue to receive standard of care treatment per patient's SCD physician.</description>
    <arm_group_label>No-Donor Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 15.00 - 40.99 years

          2. Severe sickle cell disease [Hemoglobin SS (Hb SS), Hemoglobin SC (Hb SC) or
             Hemoglobin SBeta thalassemia (Hb Sβ) genotype] with at least 1 of the following
             manifestations (a-e):

               1. Clinically significant neurologic event (stroke) or any neurological deficit
                  lasting &gt; 24 hours;

               2. History of two or more episodes of acute chest syndrome (ACS) in the 2-year
                  period preceding enrollment despite the institution of supportive care measures
                  (i.e. asthma therapy;

               3. Three or more pain crises per year in the 2-year period preceding referral
                  (required intravenous pain management in the outpatient or inpatient hospital
                  setting)

               4. Administration of regular RBC transfusion therapy, defined as receiving 8 or
                  more transfusions per year for ≥ 1 year to prevent vaso-occlusive clinical
                  complications (i.e. pain, stroke, and acute chest syndrome)

               5. An echocardiographic finding of tricuspid valve regurgitant jet (TRJ) velocity ≥
                  2.7 m/sec.

          3. Adequate physical function as measured by all of the following:

               1. Karnofsky/Lansky performance score &gt; or equal to 60

               2. Cardiac function: Left ventricular ejection fraction (LVEF) &gt; 40%; or LV
                  shortening fraction &gt; 26% by cardiac echocardiogram or by Multi Gated
                  Acquisition Scan (MUGA).

               3. Pulmonary function: Pulse oximetry with a baseline O2 saturation of ≥ 85% and
                  Diffusing capacity of the lung for carbon monoxide (DLCO) &gt; 40% (corrected for
                  hemoglobin)

               4. Renal function: Serum creatinine ≤ 1.5 x the upper limit of normal for age as
                  per local laboratory and 24 hour urine creatinine clearance &gt;70 mL/min; or GFR &gt;
                  70 mL/min/1.73 m2 by radionuclide Glomerular Filtration Rate (GFR).

               5. Hepatic function: Serum conjugated (direct) bilirubin &lt; 2x upper limit of normal
                  for age as per local laboratory; alanine aminotransferase (ALT) and aspartate
                  aminotransferase (AST) &lt; 5 times upper limit of normal as per local laboratory.
                  Patients with hyperbilirubinemia as a consequence of hyperhemolysis, or who
                  experience a sudden, profound change in the serum hemoglobin after a RBC
                  transfusion are not excluded.

        Exclusion Criteria:

          1. HLA typing prior to referral (consultation with HCT physician). However, if a subject
             has had HLA typing with accompanying documentation that relatives were not HLA typed
             and that a search of the unrelated donor registry was not performed the subject will
             be considered eligible. Documentation will be reviewed and adjudicated by the
             Protocol Officer or his/her designee.

          2. Uncontrolled bacterial, viral or fungal infection in the 6 weeks before enrollment.

          3. Seropositivity for HIV.

          4. Previous HCT.

          5. Participation in a clinical trial in which the patient received an investigational
             drug or device must be discontinued at enrollment.

          6. A history of substance abuse as defined by version IV of the Diagnostic &amp; Statistical
             Manual of Mental Disorders (DSM IV).

          7. Demonstrated lack of compliance with prior medical care (determined by referring
             physician).

          8. Pregnant or breast feeding females.

          9. Inability to receive HCT due to alloimmunization, defined as the inability to receive
             packed red blood cell (pRBC) transfusion therapy.

         10. Unwillingness to use approved contraception method from time of biologic assignment
             until discontinuation of all immunosuppressive medications if assignment at biologic
             assignment would be to donor arm.

        Additional Eligibility Criteria for Transplant after Biologic Assignment to the Donor Arm:

        Participants assigned to the Donor Arm at the time of biologic assignment are subject to
        additional transplant eligibility criteria as specified below. Additional, repeat clinical
        assessments prior to transplant should be obtained in accordance with institutional
        policies and standards of care in the interest of good clinical practice.

          1. Participants who are receiving ≥8 packed red blood cell transfusions for ≥1 year or
             have received ≥20 packed red blood cell transfusions (cumulative) will undergo liver
             MRI for estimation of hepatic iron content. Liver biopsy is indicated for hepatic
             iron content ≥7 mg Fe/gm liver dry weight. Histological examination must document the
             absence of cirrhosis, bridging fibrosis and active hepatitis. The absence of bridging
             fibrosis will be determined using the histological grading and staging scale as
             described by Ishak and colleagues (1995) as described in the Manual of Operating
             Procedures.

          2. Cerebral MRI/MRA within 30 days prior to initiation of transplant conditioning. If
             there is clinical or radiologic evidence of a recent neurologic event (such as stroke
             or transient ischemic attack) subjects will be deferred for at least 6 months with
             repeat cerebral MRI/MRA to ensure stabilization of the neurologic event prior to
             proceeding to transplantation.

          3. Absence of donor specific HLA antibodies (section 2.5)

          4. Documentation of participant's willingness to use approved contraception method until
             discontinuation of all immunosuppressive medications is to be documented in the
             medical record corresponding with the consent conference.

          5. The HLA-matched donor must be medically fit to donate and willing to donate bone
             marrow.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mary Eapen, MD</last_name>
    <role>Study Director</role>
    <affiliation>Center for International Blood and Marrow Transplant Research</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Heather Wittsack</last_name>
    <email>hwittsack@emmes.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Adam Mendizabal, PhD</last_name>
    <email>amendizabal@emmes.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Benioff Children's Hospital at Oakland</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94609</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Walters</last_name>
      <email>MWalters@mail.cho.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sandhya Kharbanda</last_name>
      <email>ksandhya@stanford.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Colorado Denver</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kathryn Hassells</last_name>
      <email>Kathryn.hassell@ucdenver.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's National Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Allistair Abraham</last_name>
      <email>AAbraham@childrensnational.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Florida Gainsville</name>
      <address>
        <city>Gainsville</city>
        <state>Florida</state>
        <zip>32611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Paul Castillo</last_name>
      <email>castillopa@ufl.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lazaros Lekakis</last_name>
      <email>LLekakis@med.miami.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Healthcare of Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lakshmanan Krishnamurti</last_name>
      <email>lakshmanan.krishnamurti@emory.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Edmund Waller</last_name>
      <email>ewaller@emory.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Georgia Regents University Medical Center</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jeremy Pantin</last_name>
      <email>JPANTIN@gru.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ann &amp; Robert H. Lurie Children's Hospital of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sonali Chaudhury</last_name>
      <email>schauhury@luriechildrens.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>John Cunninghan</last_name>
      <email>jcunning@peds.bsd.uchicago.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arunkumar Modi</last_name>
      <email>Arunkumar-modi@uiowa.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kansas University Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sunil Abhyankar</last_name>
      <email>sabhyankar@kumc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of New Orleans</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70118</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lolie Yu</last_name>
      <email>lyu@lsuhsc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Boston University</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Elizabeth Klings</last_name>
      <email>klingon@bu.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute/Children's Hospital of Boston</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Catherine Ju-Ying Wu, MD</last_name>
      <email>cwu@partners.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Michigan Medical Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Greg Yanik</last_name>
      <email>gyanik@med.umich.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Barbara Ann Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Paul Swerdlow</last_name>
      <email>swerdlow@karmanos.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Mississippi Medical Center</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dana Delaski</last_name>
      <email>ddelaski@umc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Washington University/St. Louis Children's Hospital</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shalini Shenoy</last_name>
      <email>Shenoy@kids.wustl.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jennifer Krajewski</last_name>
      <email>JKrajewski@HackensackUMC.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center/Albert Einstein School of Medicine</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Murali Janakiram</last_name>
      <email>mjanakir06@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cohen Children's Medical Center</name>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <zip>11040</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Indira Sahdev</last_name>
      <email>ISahdev@northwell.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Long Island Jewish Medical Center</name>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <zip>11040</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ruthee-Lu Bayer</last_name>
      <email>RBayer@NSHS.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>John Levine, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center/Morgan Stanley Children's Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Monica Bhatia</last_name>
      <email>mb2476@cumc.columbia.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical College</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tsiporah Shore</last_name>
      <email>Tbs2001@med.cornell.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of North Carolina Hospital at Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27516</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kimberly Kasow</last_name>
      <email>kimberly_kasow@med.unc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Keith Sullivan</last_name>
      <email>keith.sullivan@duke.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Steven Devine, MD</last_name>
      <email>steven.devine@osumc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tim Olsen</last_name>
      <email>olsont@email.chop.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Cancer Institute</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mark Vanderlugt</last_name>
      <email>mark.vanderlugt@chp.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jennifer Jaroscak</last_name>
      <email>jaroscak@musc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine/The Methodist Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rammurti Kamble</last_name>
      <email>RTKamble@houstonmethodist.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Texas/MD Anderson CRC</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Uday Popat</last_name>
      <email>upopat@mdanderson.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christina Wiedl</last_name>
      <email>cwiedl@vcu.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Health Network/Toronto General Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1L7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Auro Viswabandya</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.bmtctn.net/</url>
    <description>Blood and Marrow Transplant Clinical Trials Network Website</description>
  </link>
  <link>
    <url>https://bethematch.org/</url>
    <description>National Marrow Donor Program</description>
  </link>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 7, 2017</lastchanged_date>
  <firstreceived_date>May 6, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sickle Cell Disease</keyword>
  <keyword>Young Adults</keyword>
  <keyword>Phase II Trial</keyword>
  <keyword>Hematopoietic Cell Transplantation (HCT)</keyword>
  <keyword>Human Leukocyte Antigen (HLA)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anemia, Sickle Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Findings will be published in a manuscript.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
